therapeuticЮжно-Российский журнал терапевтической практикиSouth Russian Journal of Therapeutic Practice2712-81563033-8344РостГМУ10.21886/2712-8156-2023-4-1-19-27therapeutic-311Research ArticleОБЗОРЫREVIEWSОсобенности развития, возможности профилактики и лечения фибрилляции предсердий у больных сахарным диабетомFeatures of development, the possibility of prevention and treatment of atrial fibrillation in patients with diabetes mellitushttps://orcid.org/0000-0003-1510-9204КанорскийС. Г.KanorskiiS. G.

Канорский Сергей Григорьевич, д.м.н., профессор, заведующий кафедрой терапии №2 факультета повышения квалификации и профессиональной переподготовки

Краснодар

Sergey G. Kanorskii, Dr. Sci. (Med.), Prof., Head of the Department of Therapy No. 2, Faculty of Advanced Training and Professional Retraining

Krasnodar

kanorskysg@mail.ruhttps://orcid.org/0000-0002-7236-7341КоваленкоЮ. С.KovalenkoYu. S.

Коваленко Юлия Сергеевна, к.м.н., доцент кафедры эндокринологии факультета повышения квалификации и профессиональной переподготовки

Краснодар

Yulia S. Kovalenko, С. Med. Sci., Associate Professor of the Department of endocrinology, Faculty of Advanced Training and Professional Retraining

Krasnodar

julendo@mail.ruФГБОУ ВО «Кубанский государственный медицинский университет» Минздрава РоссииРоссияKuban State Medical UniversityRussian Federation202328032023411927Copyright © Канорский С.Г., Коваленко Ю.С., 20232023Канорский С.Г., Коваленко Ю.С.Kanorskii S.G., Kovalenko Y.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.therapeutic-j.ru/jour/article/view/311

Сахарный диабет (СД) является одним из сильных независимых факторов риска развития фибрилляции предсердий (ФП). Их сочетание встречается всё чаще, создавая у пациентов высокий риск осложнений и неблагоприятного исхода. Проведены поиск и анализ 8907 литературных источников из баз данных «Scopus», «Web of Science», «PubMed/MedLine», «The CochraneLibrary» по ключевым словам «diabetes mellitus», «atrial fibrillation», «glycemic control», «hypoglycemic therapy». В обзоре изложены современные представления о механизмах, лежащих в основе развития ФП при СД, а также о влиянии отдельных классов сахароснижающих и других препаратов на риск возникновения ФП, некоторые особенности лечения ФП при её сочетании с СД. 

Diabetes mellitus (DM) is one of the strongest independent risk factors for the development of atrial fibrillation (AF). Their combination is increasingly common, creating a high risk of complications and poor outcome in patients. A search and analysis of 8907 literature sources from the Scopus, Web of Science, PubMed/MedLine, The CochraneLibrary databases was carried out for the keywords "diabetes mellitus", "atrial fibrillation", "glycemic control", "hypoglycemic therapy". The review presents current ideas about the mechanisms underlying the development of AF in DM, as well as the effect of certain classes of hypoglycemic and other drugs on the risk of AF, some features of the treatment of AF in combination with DM.

обзорсахарный диабет 2-го типафибрилляция предсердийсахароснижающая терапияreviewtype 2 diabetesatrial fibrillationhypoglycemic therapyИсследование не имело спонсорской поддержки.ReferencesSun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. doi: 10.1016/j.diabres.2021.109119.Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. doi: 10.1016/j.diabres.2021.109119.Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study Lancet Diabetes Endocrinol. 2022;10(5):311-321. doi: 10.1016/S2213-8587(22)00044-4.Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study Lancet Diabetes Endocrinol. 2022;10(5):311-321. doi: 10.1016/S2213-8587(22)00044-4.Ogurtsova K, Guariguata L, Barengo NC, Ruiz PL, Sacre JW, Karuranga S, et al. IDF diabetes Atlas: Global estimates of undiagnosed diabetes in adults for 2021. Diabetes Res Clin Pract. 2022;183:109118. doi: 10.1016/j.diabres.2021.109118.Ogurtsova K, Guariguata L, Barengo NC, Ruiz PL, Sacre JW, Karuranga S, et al. IDF diabetes Atlas: Global estimates of undiagnosed diabetes in adults for 2021. Diabetes Res Clin Pract. 2022;183:109118. doi: 10.1016/j.diabres.2021.109118.Čarná Z, Osmančík P. The effect of obesity, hypertension, diabetes mellitus, alcohol, and sleep apnea on the risk of atrial fibrillation. Physiol Res. 2021;70(Suppl4):S511-S525. doi: 10.33549/physiolres.934744.Čarná Z, Osmančík P. The effect of obesity, hypertension, diabetes mellitus, alcohol, and sleep apnea on the risk of atrial fibrillation. Physiol Res. 2021;70(Suppl4):S511-S525. doi: 10.33549/physiolres.934744.Vio R, Giordani AS, Alturki A, Čulić V, Vitale R, China P, et al. Prevalence of asymptomatic atrial fibrillation among multimorbid elderly patients: diagnostic implications. Minerva Cardiol Angiol. 2022;70(5):583-593. doi: 10.23736/S2724-5683.22.05894-X.Vio R, Giordani AS, Alturki A, Čulić V, Vitale R, China P, et al. Prevalence of asymptomatic atrial fibrillation among multimorbid elderly patients: diagnostic implications. Minerva Cardiol Angiol. 2022;70(5):583-593. doi: 10.23736/S2724-5683.22.05894-X.Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. doi: 10.1093/eurheartj/ehaa612.Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. doi: 10.1093/eurheartj/ehaa612.Bisson A, Bodin A, Fauchier G, Herbert J, Angoulvant D, Ducluzeau PH, et al. Sex, age, type of diabetes and incidence of atrial fibrillation in patients with diabetes mellitus: a nationwide analysis. Cardiovasc Diabetol. 2021;20(1):24. doi: 10.1186/s12933-021-01216-7.Bisson A, Bodin A, Fauchier G, Herbert J, Angoulvant D, Ducluzeau PH, et al. Sex, age, type of diabetes and incidence of atrial fibrillation in patients with diabetes mellitus: a nationwide analysis. Cardiovasc Diabetol. 2021;20(1):24. doi: 10.1186/s12933-021-01216-7.Gherasim L. Association of Atrial Fibrillation with Diabetes Mellitus, High Risk Comorbidities. Maedica (Bucur). 2022;17(1):143-152. doi: 10.26574/maedica.2022.17.1.143.Gherasim L. Association of Atrial Fibrillation with Diabetes Mellitus, High Risk Comorbidities. Maedica (Bucur). 2022;17(1):143-152. doi: 10.26574/maedica.2022.17.1.143.Wang A, Green JB, Halperin JL, Piccini JP Sr. Atrial Fibrillation and Diabetes Mellitus: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;74(8):1107-1115. doi: 10.1016/j.jacc.2019.07.020.Wang A, Green JB, Halperin JL, Piccini JP Sr. Atrial Fibrillation and Diabetes Mellitus: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;74(8):1107-1115. doi: 10.1016/j.jacc.2019.07.020.Bohne LJ, Johnson D, Rose RA, Wilton SB, Gillis AM. The Association Between Diabetes Mellitus and Atrial Fibrillation: Clinical and Mechanistic Insights. Front Physiol. 2019;10:135. doi: 10.3389/fphys.2019.00135.Bohne LJ, Johnson D, Rose RA, Wilton SB, Gillis AM. The Association Between Diabetes Mellitus and Atrial Fibrillation: Clinical and Mechanistic Insights. Front Physiol. 2019;10:135. doi: 10.3389/fphys.2019.00135.Harada M, Nattel S. Implications of Inflammation and Fibrosis in Atrial Fibrillation Pathophysiology. Card Electrophysiol Clin. 2021;13(1):25-35. doi: 10.1016/j.ccep.2020.11.002.Harada M, Nattel S. Implications of Inflammation and Fibrosis in Atrial Fibrillation Pathophysiology. Card Electrophysiol Clin. 2021;13(1):25-35. doi: 10.1016/j.ccep.2020.11.002.Spartalis M, Pantelidis P, Kontogiannis C, Paschou SA, Spartalis E, Iliopoulos DC, et al. The Complex Relationship Between Diabetes and Cardiac Arrhythmias: Pathophysiology and Mechanisms. Curr Pharm Des. 2022;28(26):2129-2130. doi: 10.2174/1381612828666220720095433.Spartalis M, Pantelidis P, Kontogiannis C, Paschou SA, Spartalis E, Iliopoulos DC, et al. The Complex Relationship Between Diabetes and Cardiac Arrhythmias: Pathophysiology and Mechanisms. Curr Pharm Des. 2022;28(26):2129-2130. doi: 10.2174/1381612828666220720095433.Aune D, Feng T, Schlesinger S, Janszky I, Norat T, Riboli E. Diabetes mellitus, blood glucose and the risk of atrial fibrillation: A systematic review and meta-analysis of cohort studies. J Diabetes Complications. 2018;32(5):501-511. doi: 10.1016/j.jdiacomp.2018.02.004.Aune D, Feng T, Schlesinger S, Janszky I, Norat T, Riboli E. Diabetes mellitus, blood glucose and the risk of atrial fibrillation: A systematic review and meta-analysis of cohort studies. J Diabetes Complications. 2018;32(5):501-511. doi: 10.1016/j.jdiacomp.2018.02.004.Zhao H, Liu M, Chen Z, Mei K, Yu P, Xie L. Dose-response analysis between hemoglobin A1c and risk of atrial fibrillation in patients with and without known diabetes. PLoS One. 2020;15(2):e0227262. doi: 10.1371/journal.pone.0227262.Zhao H, Liu M, Chen Z, Mei K, Yu P, Xie L. Dose-response analysis between hemoglobin A1c and risk of atrial fibrillation in patients with and without known diabetes. PLoS One. 2020;15(2):e0227262. doi: 10.1371/journal.pone.0227262.Baek Y, Yang P, Kim T, Uhm J, Park J, Pak H, et al. Associations of abdominal obesity and new-onset atrial fibrillation in the general population. J Am Heart Assoc. 2022;6(6):e004705. doi: 10.1161/JAHA.116.004705.Baek Y, Yang P, Kim T, Uhm J, Park J, Pak H, et al. Associations of abdominal obesity and new-onset atrial fibrillation in the general population. J Am Heart Assoc. 2022;6(6):e004705. doi: 10.1161/JAHA.116.004705.Fatemi O, Yuriditsky E, Tsioufis C, Tsachris D, Morgan T, Basile J, et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). Am J Cardiol. 2014;114(8):1217-22. doi: 10.1016/j.amjcard.2014.07.045.Fatemi O, Yuriditsky E, Tsioufis C, Tsachris D, Morgan T, Basile J, et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). Am J Cardiol. 2014;114(8):1217-22. doi: 10.1016/j.amjcard.2014.07.045.Bell DSH, Goncalves E. Atrial fibrillation and type 2 diabetes: Prevalence, etiology, pathophysiology and effect of anti-diabetic therapies. Diabetes Obes Metab. 2019;21(2):210-217. doi: 10.1111/dom.13512.Bell DSH, Goncalves E. Atrial fibrillation and type 2 diabetes: Prevalence, etiology, pathophysiology and effect of anti-diabetic therapies. Diabetes Obes Metab. 2019;21(2):210-217. doi: 10.1111/dom.13512.Hsu JC, Yang YY, Chuang SL, Yu CC, Lin LY. Higher long-term visit-to-visit glycemic variability predicts new-onset atrial fibrillation in patients with diabetes mellitus. Cardiovasc Diabetol. 2021;20(1):148. doi: 10.1186/s12933-021-01341-3.Hsu JC, Yang YY, Chuang SL, Yu CC, Lin LY. Higher long-term visit-to-visit glycemic variability predicts new-onset atrial fibrillation in patients with diabetes mellitus. Cardiovasc Diabetol. 2021;20(1):148. doi: 10.1186/s12933-021-01341-3.Liou YS, Yang FY, Chen HY, Jong GP. Antihyperglycemic drugs use and new-onset atrial fibrillation: A population-based nested case control study. PLoS One. 2018;13(8):e0197245. doi: 10.1371/journal.pone.0197245.Liou YS, Yang FY, Chen HY, Jong GP. Antihyperglycemic drugs use and new-onset atrial fibrillation: A population-based nested case control study. PLoS One. 2018;13(8):e0197245. doi: 10.1371/journal.pone.0197245.Chang SH, Wu LS, Chiou MJ, Liu JR, Yu KH, Kuo CF, et al. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. Cardiovasc Diabetol. 2014;13:123. doi: 10.1186/s12933-014-0123-x.Chang SH, Wu LS, Chiou MJ, Liu JR, Yu KH, Kuo CF, et al. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. Cardiovasc Diabetol. 2014;13:123. doi: 10.1186/s12933-014-0123-x.Zhang Z, Zhang X, Korantzopoulos P, Letsas KP, Tse G, Gong M, et al. Thiazolidinedione use and atrial fibrillation in diabetic patients: a meta-analysis. BMC Cardiovasc Disord. 2017;17(1):96. doi: 10.1186/s12872-017-0531-4.Zhang Z, Zhang X, Korantzopoulos P, Letsas KP, Tse G, Gong M, et al. Thiazolidinedione use and atrial fibrillation in diabetic patients: a meta-analysis. BMC Cardiovasc Disord. 2017;17(1):96. doi: 10.1186/s12872-017-0531-4.Chang CY, Yeh YH, Chan YH, Liu JR, Chang SH, Lee HF, et al. Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan. Cardiovasc Diabetol. 2017;16(1):159. doi: 10.1186/s12933-017-0640-5.Chang CY, Yeh YH, Chan YH, Liu JR, Chang SH, Lee HF, et al. Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan. Cardiovasc Diabetol. 2017;16(1):159. doi: 10.1186/s12933-017-0640-5.Patoulias DI, Boulmpou A, Teperikidis E, Katsimardou A, Siskos F, Doumas M, et al. Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials. World J Cardiol. 2021;13(10):585-592. doi: 10.4330/wjc.v13.i10.585.Patoulias DI, Boulmpou A, Teperikidis E, Katsimardou A, Siskos F, Doumas M, et al. Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials. World J Cardiol. 2021;13(10):585-592. doi: 10.4330/wjc.v13.i10.585.Qin J, Song L. Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials. BMC Endocr Disord. 2022;22(1):125. doi: 10.1186/s12902-022-01036-0.Qin J, Song L. Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials. BMC Endocr Disord. 2022;22(1):125. doi: 10.1186/s12902-022-01036-0.Heuvelman VD, Van Raalte DH, Smits MM. Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes. Cardiovasc Res. 2020;116(5):916-930. doi: 10.1093/cvr/cvz323.Heuvelman VD, Van Raalte DH, Smits MM. Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes. Cardiovasc Res. 2020;116(5):916-930. doi: 10.1093/cvr/cvz323.Kusayama T, Wan J, Yuan Y, Chen PS. Neural Mechanisms and Therapeutic Opportunities for Atrial Fibrillation. Methodist Debakey Cardiovasc J. 2021;17(1):43-47. doi: 10.14797/FVDN2224.Kusayama T, Wan J, Yuan Y, Chen PS. Neural Mechanisms and Therapeutic Opportunities for Atrial Fibrillation. Methodist Debakey Cardiovasc J. 2021;17(1):43-47. doi: 10.14797/FVDN2224.Fauchier G, Bisson A, Bodin A, Herbert J, Angoulvant D, Ducluzeau PH, et al. Glucose-lowering drug use and new-onset atrial fibrillation in patients with diabetes mellitus. Diabetologia. 2021;64(11):2602-2605. doi: 10.1007/s00125-021-05551-y.Fauchier G, Bisson A, Bodin A, Herbert J, Angoulvant D, Ducluzeau PH, et al. Glucose-lowering drug use and new-onset atrial fibrillation in patients with diabetes mellitus. Diabetologia. 2021;64(11):2602-2605. doi: 10.1007/s00125-021-05551-y.Hamedi Z, Mishriky BM, Okunrintemi V, Powell JR, Cummings DM. GLP-1 RA and atrial fibrillation in the cardiovascular outcome trials. Diabetes Metab Res Rev. 2021;37(5):e3436. doi: 10.1002/dmrr.3436.Hamedi Z, Mishriky BM, Okunrintemi V, Powell JR, Cummings DM. GLP-1 RA and atrial fibrillation in the cardiovascular outcome trials. Diabetes Metab Res Rev. 2021;37(5):e3436. doi: 10.1002/dmrr.3436.Shi W, Zhang W, Zhang D, Ren G, Wang P, Gao L, et al. Comparison of the effect of glucose-lowering agents on the risk of atrial fibrillation: A network meta-analysis. Heart Rhythm. 2021;18(7):1090-1096. doi: 10.1016/j.hrthm.2021.03.007.Shi W, Zhang W, Zhang D, Ren G, Wang P, Gao L, et al. Comparison of the effect of glucose-lowering agents on the risk of atrial fibrillation: A network meta-analysis. Heart Rhythm. 2021;18(7):1090-1096. doi: 10.1016/j.hrthm.2021.03.007.Li W, Chen X, Xie X, Xu M, Xu L, Liu P, et al. Comparison of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide Receptor Agonists for Atrial Fibrillation in Type 2 Diabetes Mellitus: Systematic Review With Network Meta-analysis of Randomized Controlled Trials. J Cardiovasc Pharmacol. 2022;79(3):281-288. doi: 10.1097/FJC.0000000000001197.Li W, Chen X, Xie X, Xu M, Xu L, Liu P, et al. Comparison of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide Receptor Agonists for Atrial Fibrillation in Type 2 Diabetes Mellitus: Systematic Review With Network Meta-analysis of Randomized Controlled Trials. J Cardiovasc Pharmacol. 2022;79(3):281-288. doi: 10.1097/FJC.0000000000001197.Lan NSR, Fegan PG, Yeap BB, Dwivedi G. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions. ESC Heart Fail. 2019;6(5):927-935. doi: 10.1002/ehf2.12505.Lan NSR, Fegan PG, Yeap BB, Dwivedi G. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions. ESC Heart Fail. 2019;6(5):927-935. doi: 10.1002/ehf2.12505.Okunrintemi V, Mishriky BM, Powell JR, Cummings DM. Sodium-glucose co-transporter-2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials. Diabetes Obes Metab. 2021;23(1):276-280. doi: 10.1111/dom.14211.Okunrintemi V, Mishriky BM, Powell JR, Cummings DM. Sodium-glucose co-transporter-2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials. Diabetes Obes Metab. 2021;23(1):276-280. doi: 10.1111/dom.14211.Yurista SR, Silljé HHW, Rienstra M, de Boer RA, Westenbrink BD. Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes? Cardiovasc Diabetol. 2020;19(1):5. doi: 10.1186/s12933-019-0984-0.Yurista SR, Silljé HHW, Rienstra M, de Boer RA, Westenbrink BD. Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes? Cardiovasc Diabetol. 2020;19(1):5. doi: 10.1186/s12933-019-0984-0.Arow M, Waldman M, Yadin D, Nudelman V, Shainberg A, Abraham NG, et al. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy. Cardiovasc Diabetol. 2020;19(1):7. doi: 10.1186/s12933-019-0980-4.Arow M, Waldman M, Yadin D, Nudelman V, Shainberg A, Abraham NG, et al. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy. Cardiovasc Diabetol. 2020;19(1):7. doi: 10.1186/s12933-019-0980-4.Raza S, Osasan S, Sethia S, Batool T, Bambhroliya Z, Sandrugu J, et al. A Systematic Review of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Sympathetic Nervous System Inhibition: An Underrated Mechanism of Cardiorenal Protection. Cureus. 2022;14(6):e26313. doi: 10.7759/cureus.26313.Raza S, Osasan S, Sethia S, Batool T, Bambhroliya Z, Sandrugu J, et al. A Systematic Review of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Sympathetic Nervous System Inhibition: An Underrated Mechanism of Cardiorenal Protection. Cureus. 2022;14(6):e26313. doi: 10.7759/cureus.26313.Zelniker TA, Bonaca MP, Furtado RHM, Mosenzon O, Kuder JF, Murphy SA, et al. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial. Circulation. 2020;141(15):1227-1234. doi: 10.1161/CIRCULATIONAHA.119.044183.Zelniker TA, Bonaca MP, Furtado RHM, Mosenzon O, Kuder JF, Murphy SA, et al. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial. Circulation. 2020;141(15):1227-1234. doi: 10.1161/CIRCULATIONAHA.119.044183.Fernandes GC, Fernandes A, Cardoso R, Penalver J, Knijnik L, Mitrani RD, et al. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials. Heart Rhythm. 2021;18(7):1098-1105. doi: 10.1016/j.hrthm.2021.03.028.Fernandes GC, Fernandes A, Cardoso R, Penalver J, Knijnik L, Mitrani RD, et al. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials. Heart Rhythm. 2021;18(7):1098-1105. doi: 10.1016/j.hrthm.2021.03.028.Zheng RJ, Wang Y, Tang JN, Duan JY, Yuan MY, Zhang JY. Association of SGLT2 Inhibitors With Risk of Atrial Fibrillation and Stroke in Patients With and Without Type 2 Diabetes: A Systemic Review and Meta-Analysis of Randomized Controlled Trials. J Cardiovasc Pharmacol. 2022;79(2):e145-e152. doi: 10.1097/FJC.0000000000001183.Zheng RJ, Wang Y, Tang JN, Duan JY, Yuan MY, Zhang JY. Association of SGLT2 Inhibitors With Risk of Atrial Fibrillation and Stroke in Patients With and Without Type 2 Diabetes: A Systemic Review and Meta-Analysis of Randomized Controlled Trials. J Cardiovasc Pharmacol. 2022;79(2):e145-e152. doi: 10.1097/FJC.0000000000001183.Butt JH, Docherty KF, Jhund PS, de Boer RA, Böhm M, Desai AS, et al. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. Eur J Heart Fail. 2022;24(3):513-525. doi: 10.1002/ejhf.2381.Butt JH, Docherty KF, Jhund PS, de Boer RA, Böhm M, Desai AS, et al. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. Eur J Heart Fail. 2022;24(3):513-525. doi: 10.1002/ejhf.2381.Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015;386(9989):154-62. doi: 10.1016/S0140-6736(14)61774-8.Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015;386(9989):154-62. doi: 10.1016/S0140-6736(14)61774-8.Artola Arita V, Van Veldhuisen DJ, Rienstra M. Dapagliflozin effect on heart failure with prevalent or new-onset atrial fibrillation. Eur J Heart Fail. 2022;24(3):526-528. doi: 10.1002/ejhf.2443.Artola Arita V, Van Veldhuisen DJ, Rienstra M. Dapagliflozin effect on heart failure with prevalent or new-onset atrial fibrillation. Eur J Heart Fail. 2022;24(3):526-528. doi: 10.1002/ejhf.2443.Ling AW, Chan CC, Chen SW, Kao YW, Huang CY, Chan YH, et al. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors. Cardiovasc Diabetol. 2020;19(1):188. doi: 10.1186/s12933-020-01162-w.Ling AW, Chan CC, Chen SW, Kao YW, Huang CY, Chan YH, et al. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors. Cardiovasc Diabetol. 2020;19(1):188. doi: 10.1186/s12933-020-01162-w.Hsiao FC, Yen KC, Chao TF, Chen SW, Chan YH, Chu PH. New-Onset Atrial Fibrillation in Patients With Type 2 Diabetes Treated With Novel Glucose-Lowering Therapies. J Clin Endocrinol Metab. 2022;107(9):2493-2499. doi: 10.1210/clinem/dgac402.Hsiao FC, Yen KC, Chao TF, Chen SW, Chan YH, Chu PH. New-Onset Atrial Fibrillation in Patients With Type 2 Diabetes Treated With Novel Glucose-Lowering Therapies. J Clin Endocrinol Metab. 2022;107(9):2493-2499. doi: 10.1210/clinem/dgac402.Chan YH, Chao TF, Chen SW, Lee HF, Li PR, Chen WM, et al. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study. Cardiovasc Diabetol. 2022;21(1):118. doi: 10.1186/s12933-022-01549-x.Chan YH, Chao TF, Chen SW, Lee HF, Li PR, Chen WM, et al. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study. Cardiovasc Diabetol. 2022;21(1):118. doi: 10.1186/s12933-022-01549-x.Marfella R, Sasso FC, Siniscalchi M, Cirillo M, Paolisso P, Sardu C, et al. Brief episodes of silent atrial fibrillation predict clinical vascular brain disease in type 2 diabetic patients. J Am Coll Cardiol. 2013;62(6):525-30. doi: 10.1016/j.jacc.2013.02.091.Marfella R, Sasso FC, Siniscalchi M, Cirillo M, Paolisso P, Sardu C, et al. Brief episodes of silent atrial fibrillation predict clinical vascular brain disease in type 2 diabetic patients. J Am Coll Cardiol. 2013;62(6):525-30. doi: 10.1016/j.jacc.2013.02.091.Engström A, Wintzell V, Melbye M, Hviid A, Eliasson B, Gudbjörnsdottir S, et al. Sodium-Glucose Cotransporter 2 Inhibitor Treatment and Risk of Atrial Fibrillation: Scandinavian Cohort Study. Diabetes Care. 2022 Dec 12:dc220714. doi: 10.2337/dc22-0714. Online ahead of print.Engström A, Wintzell V, Melbye M, Hviid A, Eliasson B, Gudbjörnsdottir S, et al. Sodium-Glucose Cotransporter 2 Inhibitor Treatment and Risk of Atrial Fibrillation: Scandinavian Cohort Study. Diabetes Care. 2022 Dec 12:dc220714. doi: 10.2337/dc22-0714. Online ahead of print.Chaugai S, Meng WY, Ali Sepehry A. Effects of RAAS Blockers on Atrial Fibrillation Prophylaxis: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Cardiovasc Pharmacol Ther. 2016;21(4):388-404. doi: 10.1177/1074248415619490.Chaugai S, Meng WY, Ali Sepehry A. Effects of RAAS Blockers on Atrial Fibrillation Prophylaxis: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Cardiovasc Pharmacol Ther. 2016;21(4):388-404. doi: 10.1177/1074248415619490.Filippatos G, Bakris GL, Pitt B, Agarwal R, Rossing P, Ruilope LM, et al. Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. J Am Coll Cardiol. 2021;78(2):142-152. doi: 10.1016/j.jacc.2021.04.079.Filippatos G, Bakris GL, Pitt B, Agarwal R, Rossing P, Ruilope LM, et al. Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. J Am Coll Cardiol. 2021;78(2):142-152. doi: 10.1016/j.jacc.2021.04.079.Zhang Y, Wang J, Jiang L, Wang T, Li Z, Fu X, et al. Network meta‑analysis on the efficacy and safety of finerenone versus SGLT2 inhibitors on reducing new‑onset of atrial fibrillation in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetol Metab Syndr. 2022;14(1):156. doi: 10.1186/s13098-022-00929-3.Zhang Y, Wang J, Jiang L, Wang T, Li Z, Fu X, et al. Network meta‑analysis on the efficacy and safety of finerenone versus SGLT2 inhibitors on reducing new‑onset of atrial fibrillation in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetol Metab Syndr. 2022;14(1):156. doi: 10.1186/s13098-022-00929-3.Li X, Weber NC, Cohn DM, Hollmann MW, DeVries JH, Hermanides J, et al. Effects of Hyperglycemia and Diabetes Mellitus on Coagulation and Hemostasis. J Clin Med. 2021;10(11):2419. doi: 10.3390/jcm10112419.Li X, Weber NC, Cohn DM, Hollmann MW, DeVries JH, Hermanides J, et al. Effects of Hyperglycemia and Diabetes Mellitus on Coagulation and Hemostasis. J Clin Med. 2021;10(11):2419. doi: 10.3390/jcm10112419.Abdel‐Qadir H, Gunn M, Lega LC, Pang A, Austin PC, Singh SM, et al. Association of Diabetes Duration and Glycemic Control With Stroke Rate in Patients With Atrial Fibrillation and Diabetes: A Population-Based Cohort Study. J Am Heart Assoc. 2022; 11(4):e023643. doi: 10.1161/JAHA.121.023643.Abdel‐Qadir H, Gunn M, Lega LC, Pang A, Austin PC, Singh SM, et al. Association of Diabetes Duration and Glycemic Control With Stroke Rate in Patients With Atrial Fibrillation and Diabetes: A Population-Based Cohort Study. J Am Heart Assoc. 2022; 11(4):e023643. doi: 10.1161/JAHA.121.023643.Fangel MV, Nielsen PB, Kristensen JK, Larsen TB, Overvad TF, Lip GYH, et al. Glycemic Status and Thromboembolic Risk in Patients With Atrial Fibrillation and Type 2 Diabetes Mellitus: A Danish Cohort Study. Circ Arrhythm Electrophysiol. 2019;12(5):e007030. doi: 10.1161/CIRCEP.118.007030.Fangel MV, Nielsen PB, Kristensen JK, Larsen TB, Overvad TF, Lip GYH, et al. Glycemic Status and Thromboembolic Risk in Patients With Atrial Fibrillation and Type 2 Diabetes Mellitus: A Danish Cohort Study. Circ Arrhythm Electrophysiol. 2019;12(5):e007030. doi: 10.1161/CIRCEP.118.007030.Patti G, Lucerna M, Cavallari I, Ricottini E, Renda G, Pecen L, et al. Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation: PREFER in AF. J Am Coll Cardiol. 2017;69(4):409-419. doi: 10.1016/j.jacc.2016.10.069.Patti G, Lucerna M, Cavallari I, Ricottini E, Renda G, Pecen L, et al. Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation: PREFER in AF. J Am Coll Cardiol. 2017;69(4):409-419. doi: 10.1016/j.jacc.2016.10.069.Itzhaki Ben Zadok O, Eisen A. Use of non-vitamin K oral anticoagulants in people with atrial fibrillation and diabetes mellitus. Diabet Med. 2018;35(5):548-556. doi: 10.1111/dme.13600.Itzhaki Ben Zadok O, Eisen A. Use of non-vitamin K oral anticoagulants in people with atrial fibrillation and diabetes mellitus. Diabet Med. 2018;35(5):548-556. doi: 10.1111/dme.13600.Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021;23(10):1612-1676. doi: 10.1093/europace/euab065.Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021;23(10):1612-1676. doi: 10.1093/europace/euab065.Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020;383(14):1305-1316. doi: 10.1056/NEJMoa2019422.Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020;383(14):1305-1316. doi: 10.1056/NEJMoa2019422.Creta A, Providência R, Adragão P, de Asmundis C, Chun J, Chierchia G, et al. Impact of Type-2 Diabetes Mellitus on the Outcomes of Catheter Ablation of Atrial Fibrillation (European Observational Multicentre Study). Am J Cardiol. 2020;125(6):901-906. doi: 10.1016/j.amjcard.2019.12.037.Creta A, Providência R, Adragão P, de Asmundis C, Chun J, Chierchia G, et al. Impact of Type-2 Diabetes Mellitus on the Outcomes of Catheter Ablation of Atrial Fibrillation (European Observational Multicentre Study). Am J Cardiol. 2020;125(6):901-906. doi: 10.1016/j.amjcard.2019.12.037.Kishima H, Mine T, Fukuhara E, Kitagaki R, Asakura M, Ishihara M. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors on Outcomes After Catheter Ablation for Atrial Fibrillation. JACC Clin Electrophysiol. 2022;8(11):1393-1404. doi: 10.1016/j.jacep.2022.08.004.Kishima H, Mine T, Fukuhara E, Kitagaki R, Asakura M, Ishihara M. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors on Outcomes After Catheter Ablation for Atrial Fibrillation. JACC Clin Electrophysiol. 2022;8(11):1393-1404. doi: 10.1016/j.jacep.2022.08.004.

The authors declare that there are no conflicts of interest present.